{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:21:44Z","timestamp":1791231704648,"version":"4.1.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and objective:<\/jats:bold> Sacituzumab govitecan (SG), the first antibody-drug conjugate targeting human trophoblast cell-surface antigen 2 (Trop-2), has been approved by the Food and Drug Administration (FDA) for the treatment of advanced or metastatic breast cancer and urothelial cancer. However, there is currently a dearth of information regarding the safety profiles of SG in a large sample cohort. The objective of the present study is to investigate SG-related adverse events (AEs) in real-world settings leveraging the FDA Adverse Event Reporting System (FAERS) database to guide the safety management of clinical medication.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The FAERS database was retrospectively queried to extract reports associated with SG from April 2020 to March 2023. To identify and evaluate potential AEs in patients receiving SG, various disproportionality analyses such as reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) were employed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Overall, 2069 reports of SG as the \u201cprimary suspect\u201d were identified. Noteworthy, SG was significantly associated with an increased risk of blood lymphatic system disorders (ROR, 7.18; 95% CI, 6.58\u20137.84) and hepatobiliary disorders (ROR, 2.68; 95% CI, 2.17\u20133.30) at the System Organ Class (SOC) level. Meanwhile, 61 significant disproportionality preferred terms (PTs) simultaneously complied with all four algorithms were adopted. Therein, anemia, thrombocytopenia, neutropenia, leukopenia, diarrhea, asthenia, alopecia, and electrolyte imbalance were consistent with the common AEs described in the clinical trials and specification of SG. Furthermore, unexpected significant AEs include colitis (ROR, 12.09; 95% CI, 9.1\u201316.08), heart rate increased (ROR, 5.11; 95% CI, 3.84\u20136.79), sepsis (ROR, 4.77; 95% CI, 3.59\u20136.34), cholestasis (ROR, 6.28; 95% CI, 3.48\u201311.36), blood bilirubin increased (ROR, 4.65; 95% CI, 2.42\u20138.94) and meningitis (ROR, 7.23; 95% CI, 2.71\u201319.29) were also be detected. The median time to onset of SG-related AEs was 14 [interquartile range (IQR), 7\u201352] days, with the majority occurring within the initial month of SG treatment.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study validates the commonly known AEs and also found some potentially emerging safety issues related to SG in real-world clinical practice, which could provide valuable vigilance evidence for clinicians and pharmacists to manage the safety issues of SG.<\/jats:p>","DOI":"10.3389\/fphar.2023.1283247","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T10:38:23Z","timestamp":1699871903000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database"],"prefix":"10.3389","volume":"14","author":[{"given":"Wensheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"","journal-title":"Ann. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO clinical practice guidelines","volume":"29","author":"Bossi","year":"2018","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41523-022-00439-5","article-title":"Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis","volume":"8","author":"Carey","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"892265","DOI":"10.3389\/fmed.2022.892265","article-title":"Dysnatremia in gastrointestinal disorders","volume":"9","author":"Do","year":"2022","journal-title":"Front. Med. (Lausanne)."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","article-title":"A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B12","unstructured":"FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. News Release2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov."},{"key":"B14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: a review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"106002802311641","DOI":"10.1177\/10600280231164110","article-title":"Sacituzumab govitecan as a second-line treatment in relapsed\/refractory metastatic triple-negative breast cancer patients: a systematic review and meta-analysis","author":"Kathpalia","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ajco.12748","article-title":"Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies","volume":"14","author":"Khosravi-Shahi","year":"2018","journal-title":"Asia Pac J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/COC.0000000000000919","article-title":"Sacituzumab govitecan-hziy in breast cancer","volume":"45","author":"Kwapisz","year":"2022","journal-title":"Am. J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.3390\/ijms22147439","article-title":"Cytoprotective effect of vitamin D on doxorubicin-induced cardiac toxicity in triple negative breast cancer","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"B24","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/cancers13071566","article-title":"UGT1A1 guided cancer therapy: review of the evidence and considerations for clinical implementation","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4143\/crt.2017.562","article-title":"Randomized open label phase III trial of irinotecan Plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11-01)","volume":"51","author":"Park","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"LBA1001","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","article-title":"Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"Rugo","year":"","journal-title":"J. Clin. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"PS11","DOI":"10.1158\/1538-7445.SABCS20-PS11-09","article-title":"Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer [abstract]. Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium","volume":"81","author":"Rugo","year":"2021","journal-title":"Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"","journal-title":"NPJ Breast Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/106689690501300215","article-title":"Irinotecan-induced colitis","volume":"13","author":"Sandmeier","year":"2005","journal-title":"Int. J. Surg. Pathol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1169735","DOI":"10.3389\/fimmu.2023.1169735","article-title":"Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system","volume":"14","author":"Shu","year":"","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"","journal-title":"Cancer Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/onco.13878","article-title":"Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities","volume":"26","author":"Spring","year":"2021","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-Human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B40","unstructured":"Prescribing information. 2023"},{"key":"B41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.critrevonc.2016.01.021","article-title":"Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer","volume":"100","author":"Twelves","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ijc.34424","article-title":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"2023","journal-title":"Int. J. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1283247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T10:38:27Z","timestamp":1699871907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1283247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":44,"alternative-id":["10.3389\/fphar.2023.1283247"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1283247","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"article-number":"1283247"}}